Evidence map›Paper›PMID 39372991›Full record

ReviewSurgical neurology international2024

Emerging therapies for immunomodulation in traumatic brain injury: A systematic review and meta-analysis.

Abdulrahim Saleh Alrasheed, Mohammed Abdullah Alqadhibi, Rammaz Hussam Khoja, Abdulaziz Saad Alayyaf, Duaa Saleh Alhumoudi, Mubarak Ibrahim Aldawlan, Bedoor Obidallah Alghanmi, Fahad Salman Almutairi, Mohammed Ali Bin-Mahfooz, Lina Abdulrahim Altalhi and 3 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Surgical neurology international, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Abdulrahim Saleh AlrasheedDepartment of Surgery, College of Medicine, King Faisal University, AlAhsa, Saudi Arabia.
Mohammed Abdullah AlqadhibiDepartment of Surgery, College of Medicine, Majmaah University, Majmaah, Saudi Arabia.
Rammaz Hussam KhojaDepartment of Surgery, College of Medicine, Taibah University, Madinah, Saudi Arabia.
Abdulaziz Saad AlayyafDepartment of Surgery, College of Medicine, Prince Sattam bin Abdulaziz University, Riyadh, Saudi Arabia.
Duaa Saleh AlhumoudiDepartment of Surgery, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Mubarak Ibrahim AldawlanDepartment of Surgery, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.
Bedoor Obidallah AlghanmiDepartment of Surgery, College of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
Fahad Salman AlmutairiDepartment of Surgery, Royal College of Surgeons in Ireland, Dublin, Ireland.
Mohammed Ali Bin-MahfoozDepartment of Surgery, College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
Lina Abdulrahim AltalhiDepartment of Surgery, College of Medicine and Medical Science, Arabian Gulf University, Manama, Bahrain.
Saud Nayef AldanyowiDepartment of Surgery, College of Medicine, King Faisal University, AlAhsa, Saudi Arabia.
Abdulsalam Mohammed AleidDepartment of Surgery, College of Medicine, King Faisal University, AlAhsa, Saudi Arabia.
Awn Abdulmohsen AlessaDepartment of Neurosurgery, King Fahad Hospital, AlAhsa, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Traumatic brain injury (TBI) represents a significant global health burden, often leading to significant morbidity and mortality. Mounting evidence underscores the intricate involvement of dysregulated immune responses in TBI pathophysiology, highlighting the potential for immunomodulatory interventions to mitigate secondary injury cascades and enhance patient outcomes. Despite advancements in treatment modalities, optimizing therapeutic strategies remains a critical challenge in TBI management. To address this gap, this systematic review and meta-analysis aimed to rigorously evaluate the efficacy and safety of emerging immunomodulatory therapies in the context of TBI. Methods: We searched electronic databases such as PubMed, Scopus, Web of Science and CENTRAL for relevant studies investigating the efficacy of immunomodulatory therapies in TBI that were meticulously selected for inclusion. Two independent reviewers meticulously performed data extraction and quality assessment, adhering to predefined criteria. Both randomized controlled trials (RCTs) and observational studies reporting clinically relevant outcomes, such as mortality rates, the Glasgow coma scale, and adverse events, were meticulously scrutinized. Meta-analysis techniques were employed to assess treatment effects across studies quantitatively and analyzed using the Review Manager software (version 5.2). Results: Fourteen studies ( Conclusion: Immunomodulatory therapies did not significantly affect overall mortality, but EPO demonstrated promising results. Adverse events did not significantly differ from controls. Further research is warranted to refine TBI treatment protocols.

Indexed as

ErythropoietinImmunomodulatory therapiesTraumatic brain injuryTreatment outcomes

Identifiers

PMID39372991
PMCPMC11450791

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.